Want to see SNPHY full AI Analyst Report?
Stn1013800 Ophthalmic Solution
Blepharoptosis
Early Phase I
Completed
A Pharmacokinetics (PK) Study in Healthy Adults
Mar 11, 2025
―
Stn1013800 Ophthalmic Solution, Stn1013800 Ophthalmic Solution Liquid Base, Without Stn1013800
Blepharoptosis
Phase III
Recruiting
A Study in Chinese Patients With Acquired Blepharoptosis
Nov 08, 2024
―
Latanoprost, De-117B Eye Drops
Ocular Hypertension, Open Angle Glaucoma
Phase III
Recruiting
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
Oct 29, 2024
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Santen Pharmaceutical Co Ltd (SNPHY) have in its pipeline
SNPHY is currently developing the following drugs: Stn1013800 Ophthalmic Solution, Stn1013800 Ophthalmic Solution, Stn1013800 Ophthalmic Solution Liquid Base, Without Stn1013800, Latanoprost, De-117B Eye Drops. These drug candidates are in various stages of clinical development as the company works toward FDA approval.